No products in the cart.
Rabbit Polyclonal Phospho-BRCA2 (S3291) antibody (STJ90672)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-1:2000; ELISA 1:10000;
Recommended protocols: check protocols
Click or hover above images to see image description for BRCA2 (phospho Ser3291) Polyclonal Antibody.
Check alternative names for the antibodyExpand
BRCA2 antibody, FACD antibody, FANCD1 antibody,|BRCA 2 antibody|BRCA1/BRCA2 containing complex subunit 2 antibody|Brca2 antibody|BRCA2, DNA repair associated antibody|BRCA2_HUMAN antibody|BRCC 2 antibody|BRCC2 antibody|Breast and ovarian cancer susceptibility gene early onset antibody|breast and ovarian cancer susceptibility protein 2 antibody|Breast cancer 2 early onset antibody|Breast Cancer 2 tumor suppressor antibody|Breast cancer susceptibility protein BRCA2 antibody|Breast cancer type 2 susceptibility protein antibody|BROVCA2 antibody|FACD antibody|FAD 1 antibody|FAD antibody|FAD1 antibody|FANCB antibody|FANCD 1 antibody|FANCD antibody|FANCD1 antibody|FANCD1 gene antibody|Fanconi anemia complementation group D1 antibody|Fanconi anemia group D1 protein antibody|GLM3 antibody|mutant BRCA2 antibody|OTTHUMP00000018803 antibody|OTTHUMP00000042401 antibody|PNCA2 antibody|XRCC11 antibody|Anti-BRCA2 antibody (ab27976)
SCBT cat No: sc-293185|sc-1817|sc-28235|sc-8326|sc-1818|sc-1819|sc-21230|
BRCA2 (phospho Ser3291) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
Phospho-BRCA2 (S3291) Polyclonal Antibody detects endogenous levels of BRCA2 protein only when phosphorylated at S3291.
Synthesized phospho-peptide derived from BRCA2 (phospho Ser3291) at AA range 3230-3310
|Recommended dilution|| |
WB 1:500-1:2000; ELISA 1:10000;
|Molecular weight|| |
BRCA2 (phospho Ser3291) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
BRCA2 (phospho Ser3291) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Breast cancer type 2 susceptibility protein antibody, Fanconi anemia group D1 protein antibody
|Protein names|| |
Breast cancer type 2 susceptibility protein , Fanconi anemia group D1 protein
|Protein function|| |
Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded HR complex containing RAD51C and which is thought to play a role in DNA repair by HR. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity. In concert with NPM1, regulates centrosome duplication. Interacts with the TREX-2 complex (transcription and export complex 2) subunits PCID2 and SHFM1/DSS1, and is required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability. Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination .
|Protein tissue specificity|| |
Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen.
|Involvement in disease|| |
Breast cancer (BC) [MIM:114480]: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.; Pancreatic cancer 2 (PNCA2) [MIM:613347]: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Breast-ovarian cancer, familial, 2 (BROVCA2) [MIM:612555]: A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.; Fanconi anemia complementation group D1 (FANCD1) [MIM:605724]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Glioma 3 (GLM3) [MIM:613029]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. . Note: The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Contains 8 BRCA2 repeats.
|Protein post-translational modifications|| |
Phosphorylated by ATM upon irradiation-induced DNA damage. Phosphorylation by CHEK1 and CHEK2 regulates interaction with RAD51. Phosphorylation at Ser-3291 by CDK1 and CDK2 is low in S phase when recombination is active, but increases as cells progress towards mitosis; this phosphorylation prevents homologous recombination-dependent repair during S phase and G2 by inhibiting RAD51 binding. / Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation.
|Protein cellular localization|| |
Nucleus / Cytoplasm > cytoskeleton > microtubule organizing center > centrosome
AntibodyPlus can customize BRCA2 (phospho Ser3291) Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: